Home/Filings/4/0000950170-24-026098
4//SEC Filing

Conway Vikki L 4

Accession 0000950170-24-026098

CIK 0000818686other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:39 PM ET

Size

17.2 KB

Accession

0000950170-24-026098

Insider Transaction Report

Form 4
Period: 2024-03-03
Conway Vikki L
See "Remarks"
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2024-03-03+5,1798,107 total
  • Sale

    Ordinary Shares

    2024-03-04$13.37/sh1,490$19,9266,617 total
  • Exercise/Conversion

    Ordinary Shares

    2024-03-04+7,11713,734 total
  • Sale

    Ordinary Shares

    2024-03-04$13.37/sh2,042$27,30811,692 total
  • Exercise/Conversion

    Restricted Share Units

    2024-03-035,17915,538 total
    Ordinary Shares (5,179 underlying)
  • Exercise/Conversion

    Restricted Share Units

    2024-03-047,11714,237 total
    Ordinary Shares (7,117 underlying)
  • Award

    Restricted Share Units

    2024-03-04+33,48233,482 total
    Ordinary Shares (33,482 underlying)
Footnotes (8)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
  • [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F6]Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.
  • [F7]Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026.
  • [F8]Restricted share units were granted on March 4, 2024, with 8,370 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 8,372 vesting on March 4, 2028.

Documents

1 file

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001995297

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:39 PM ET
Size
17.2 KB